Muhammad Haroon, MD
Hematology & Oncology · Fremont, NENPI 1326048927
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $233 of the $372 with a category attached, or 62.6%. It is spread thinly across 13 manufacturers, the largest accounting for just 18.4%. 2025 is the largest year on record at $131, more than ten times the $13 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 18 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$68
- E.r. Squibb & Sons, L.L.C.$57
- Pharmacyclics LLC, An Abbvie Company$48
- Daiichi Sankyo Inc.$32
- Pfizer$26
- Servier Pharmaceuticals LLC$25
- plus $115 from 7 others
Across 115 payments — averaging $983.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seagen Inc.$106K
- Pfizer$7K
- AstraZeneca$191
What the payments were for
- Food & beverage$23363%
- Education$13937%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $68 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Pfizer | 2 | $26 |
| Servier Pharmaceuticals LLC | 1 | $25 |
| AbbVie | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| CTI Biopharma Corp. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $14 |
| GSK | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$372 in reported general payments places this provider in the 15th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 38 | $582,004 |
| CalquenceAcalabrutinib Maleate | 19 | $235,898 |
| IbrancePalbociclib | 14 | $215,852 |
| VerzenioAbemaciclib | 11 | $159,295 |
| EliquisApixaban | 70 | $44,895 |
| NivestymFilgrastim-Aafi | 13 | $7,554 |
| Anastrozole | 209 | $1,914 |
| Potassium Chloride | 99 | $1,225 |
| Dexamethasone | 48 | $908 |
| Hydroxyurea | 39 | $895 |
| Acyclovir | 59 | $709 |
| Letrozole | 58 | $641 |
| Ondansetron OdtOndansetron | 39 | $507 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 47 | $434 |
| Prochlorperazine Maleate | 47 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis, Nivestym | $26 | $268,30097 claims |
| AstraZenecaCalquence | $68 | $235,89819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Fremont
- Mojtaba AkhtariOmaha$1.8M
- Rabih FahedNorfolk$294K
- Luke NordquistOmaha$202K
- Apar Kishor GantiOmaha$138K
- Julie VoseOmaha$123K
- Peter SilbersteinOmaha$99K
- Krishna GundaboluOmaha$76K
- Vijaya BhattOmaha$58K
- Debora BrunoHastings$57K
- Pornchai JonglerthamHastings$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.